Seres Therapeutics, Inc. (MCRB)

NASDAQ: MCRB · IEX Real-Time Price · USD
1.225
-0.035 (-2.78%)
At close: Jul 19, 2024, 4:00 PM
1.230
+0.005 (0.41%)
After-hours: Jul 19, 2024, 7:51 PM EDT
-2.78%
Market Cap 185.52M
Revenue (ttm) 126.85M
Net Income (ttm) -82.68M
Shares Out 151.45M
EPS (ttm) -0.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,200,442
Open 1.260
Previous Close 1.260
Day's Range 1.150 - 1.290
52-Week Range 0.540 - 5.290
Beta 1.96
Analysts Buy
Price Target 5.75 (+369.39%)
Earnings Date Aug 6, 2024

About MCRB

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company’s lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 26, 2015
Employees 233
Stock Exchange NASDAQ
Ticker Symbol MCRB
Full Company Profile

Financial Performance

In 2023, MCRB's revenue was $126.33 million, an increase of 1672.24% compared to the previous year's $7.13 million. Losses were -$113.72 million, -54.54% less than in 2022.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for MCRB stock is "Buy." The 12-month stock price forecast is $5.75, which is an increase of 369.39% from the latest price.

Price Target
$5.75
(369.39% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass, June 07, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on June 5, 2024, ...

6 weeks ago - GlobeNewsWire

Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023

Transaction ensures Nestlé Health Science will continue to commercialize the product BRIDGEWATER, N.J. , June 6, 2024 /PRNewswire/ -- Seres Therapeutics, Inc. (Nasdaq: MCRB), announced today that it h...

6 weeks ago - PRNewsWire

Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science

Seres anticipates capital infusions, including an upfront payment, enabling the Company to fully retire its debt and extend its cash runway into Q4 2025, pending deal closure and subject to performanc...

6 weeks ago - GlobeNewsWire

Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2024 financial results and provided business updates...

2 months ago - Business Wire

Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcas...

2 months ago - Business Wire

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that enrollment is complete in the placebo-controlled Cohort 2 of...

3 months ago - Business Wire

VKTX, JANX and these biotech stocks are surging in 2024

Forget artificial intelligence stocks like Nvidia and Super Micro Computer. Biotech stocks are doing much better this year.

3 months ago - Invezz

Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2023 financial results and provided b...

4 months ago - Business Wire

Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcas...

5 months ago - Business Wire

Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that Eric Shaff, President and Chief Executive Officer of Seres T...

5 months ago - Business Wire

Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that Marella Thorell will join as Executive Vice President and Ch...

5 months ago - Business Wire

Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced preliminary key VOWST (fecal microbiota spores, live-brpk) launch...

6 months ago - Business Wire

Seres Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will present at the 42nd Annual J.P. Morgan...

7 months ago - Business Wire

Seres Therapeutics Announces Presentation of Preliminary PK/PD and Safety Data for Investigational Microbiome Therapeutic SER-155 at ASH 2023

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that preliminary clinical data from a currently enrolling Phase 1...

8 months ago - Business Wire

Seres Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023; Webcast at 3:30 p.m. ET

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will participate at the Piper Sandler 35th ...

8 months ago - Business Wire

Seres Therapeutics Reports Third Quarter 2023 Financial Results Including VOWST™ Net Sales of $7.6 Million

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported financial results for the third quarter ended September 30, 2023, ...

9 months ago - Business Wire

Seres Therapeutics to Announce Third Quarter 2023 Results on Thursday, November 2, 2023; Host Conference Call and Webcast at 8:00 a.m. EST

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will release third quarter 2023 financial results on Thur...

9 months ago - Business Wire

Seres Therapeutics to Highlight VOWST™ Data at IDWeek

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced multiple abstracts to be presented at IDWeek 2023 in Boston, Massachusetts (October 11-15, 2023), including t...

10 months ago - Business Wire

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

CAMBRIDGE, Mass. , Sept. 11, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business Developmen...

Other symbols: DNLIFHTXMRNAOMGASANA
11 months ago - PRNewsWire

Seres Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will participate at the Morgan Stanley 21st...

11 months ago - Business Wire

Seres Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported second quarter 2023 financial results and provided business update...

1 year ago - Business Wire

Seres Therapeutics to Host Second Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on August 8, 2023

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcas...

1 year ago - Business Wire

Seres Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will present at the Canaccord Genuity 43rd ...

1 year ago - Business Wire

Seres Therapeutics Named to TIME100 Most Influential Companies List

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, has been named to the “TIME100 Most Influential Companies,” a list of 100 compani...

1 year ago - Business Wire

Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs

Empress's Chemilogics™ product platform creates small molecule drugs quickly and cost-effectively The company emerges after two years of platform development with an initial commitment of $50 million ...

Other symbols: DNLIFHTXMRNAOMGASANA
1 year ago - PRNewsWire